Precision NanoSystems Announces Manufacturing Collaboration Agreement with Ajinomoto Bio-Pharma Services for GMP Manufacturing of High Quality Nanomedicines
Precision Nanosystems Inc. (PNI), a global leader in innovative solutions for the discovery, development and manufacture of novel nanoparticles medicines, announced today that it has entered into a manufacturing collaboration agreement with Ajinomoto Bio-Pharma Services. Together, PNI and Ajinomoto Bio-Pharma Services can now support clients into clinical development through to the commercialization of transformative nanomedicines using PNI’s NanoAssemblr™ Scale-Up system.
Ajinomoto Bio-Pharma Services is a contract development and manufacturing organization that offers a full range of pre-clinical and GMP manufacturing services from drug substance to fill & finish meeting clients’ needs for clinical and commercial drug product. “Ajinomoto Bio-Pharma Services has audited the PNI facilities in Vancouver and has qualified PNI’s GMP NanoAssemblr Scale-Up system and its components. We are excited to work with PNI to offer their purpose-designed manufacturing technology and unique nanomedicine expertise to our clients for the manufacture of nanoparticle-based medicines” said Kristin DeFife, Ph.D., Vice President and Head of US Operations of Ajinomoto Bio-Pharma Services.
The GMP NanoAssemblr system to be used by Ajinomoto Bio-Pharma Services is modular and customizable to suit specific clients’ needs and allows for continuous flow manufacture of nanomedicines under cGMP. Under this manufacturing collaboration, Ajinomoto Bio-Pharma Services and PNI will work together to support clients by providing a complete range of clinical development services from pre-clinical formulation, analytical and process development to GMP manufacturing of nanomedicines on the NanoAssemblr platform.
“As we continue to accelerate the creation of transformative medicines, we are pursuing strategic collaborations that enable researchers to move quickly in the drug development process. We are very pleased to announce our collaboration with Ajinomoto Bio-Pharma Services as it exemplifies our goal to provide the NanoAssemblr platform for the seamless scale up from discovery to GMP manufacturing of the next generation nanomedicines” said James Taylor, Co-Founder and CEO for PNI.
About Precision NanoSystems Inc.
Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit www.precisionnanosystems.
À propos d'Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services est une organisation de développement et de fabrication sous contrat entièrement intégrée, disposant de sites en Belgique, aux États-Unis, au Japon et en Inde. Elle propose des services complets de développement, de fabrication conforme aux normes cGMP et de conditionnement aseptique pour les principes actifs pharmaceutiques (API) à petites et grandes molécules ainsi que pour les intermédiaires. Ajinomoto Bio-Pharma Services propose un large éventail de plateformes et de capacités innovantes, allant des programmes précliniques et pilotes jusqu’aux quantités commerciales, notamment : la technologie d’expression protéique Corynex®, la synthèse d’oligonucléotides, les conjugués anticorps-médicaments (ADC), les principes actifs pharmaceutiques à haute puissance (HPAPI), la biocatalyse, la fabrication en flux continu, et bien plus encore. Ajinomoto Bio-Pharma Services s'engage à fournir un niveau élevé de qualité et de service afin de répondre aux besoins de ses clients. Pour en savoir plus : www.AjiBio-Pharma.com
